---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-123689"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T05:03:41.825009+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# XOMA pays $22M upfront for royalty interests in three women's health assets from Daré Bioscience

## Summary
- XOMA paid $22M cash to Daré for royalties on XACIATO, Ovaprene, and Sildenafil Cream.
- XOMA receives low-to-high single-digit royalties on XACIATO net sales; Organon began marketing in Q4 2023.
- Synthetic royalties: low single-digit on Ovaprene (Phase 3) and Sildenafil Cream (Phase 3-ready), decreasing after return threshold.
- XOMA also acquires a portion of a milestone payment from Bayer related to Ovaprene.
- XOMA will make upside-sharing milestone payments to Daré upon achieving a pre-specified return threshold.

## SEC filing metadata
- accession: 0001193125-24-123689
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312524123689/0001193125-24-123689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312524123689/d798315d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-123689
- JSON: https://secwatch.observer/filing/0001193125-24-123689.json
- Plain text: https://secwatch.observer/filing/0001193125-24-123689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.